The physiological role of aerobic glycolysis (also known as the Warburg effect), which is observed in many tumours, is still not fully understood. The finding that lactate dehydrogenase A (LDHA) activates RAC1 in breast cancer sheds new light on this persistently enigmatic aspect of cancer metabolism.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Signal Transduction and Targeted Therapy Open Access 23 May 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Warburg, O. Versuche an überlebendem Carcinomgewebe. Biochem. Z. 142, 317–333 (1923).
Liberti, M. V. & Locasale, J. W. The Warburg effect: how does it benefit cancer cells? Trends Biochem. Sci. 41, 211–218 (2016).
Vaupel, P. & Multhoff, G. Revisiting the Warburg effect: historical dogma versus current understanding. J. Physiol. (Lond.) 599, 1745–1757 (2021).
Valvona, C. J., Fillmore, H. L., Nunn, P. B. & Pilkington, G. J. The regulation and function of lactate dehydrogenase A: therapeutic potential in brain tumor. Brain Pathol. 26, 3–17 (2016).
Feng, Y. et al. Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy. Cancer Med. 7, 6124–6136 (2018).
Le, A. et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl Acad. Sci. USA 107, 2037–2042 (2010).
Liu, J. Metabolic enzyme LDHA activates RAC1 GTPase as a noncanonical mechanism to promote cancer. Nat. Metab. https://doi.org/10.1038/s42255-022-00708-4 (2023).
Marei, H. & Malliri, A. Rac1 in human diseases: the therapeutic potential of targeting Rac1 signaling regulatory mechanisms. Small GTPases 8, 139–163 (2017).
Osaka, N. et al. Divergent mechanisms activating RAS and small GTPases through post-translational modification. Front. Mol. Biosci. 8, 707439 (2021).
Baker, R. et al. Site-specific monoubiquitination activates Ras by impeding GTPase-activating protein function. Nat. Struct. Mol. Biol. 20, 46–52 (2013).
Gao, Y., Dickerson, J. B., Guo, F., Zheng, J. & Zheng, Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl Acad. Sci. USA 101, 7618–7623 (2004).
Hou, H. et al. The Rac1 inhibitor NSC23766 suppresses CREB signaling by targeting NMDA receptor function. J. Neurosci. 34, 14006–14012 (2014).
Dütting, S. et al. Critical off-target effects of the widely used Rac1 inhibitors NSC23766 and EHT1864 in mouse platelets. J. Thromb. Haemost. 13, 827–838 (2015).
Jin, L. et al. Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis. Oncogene 36, 3797–3806 (2017).
Urbańska, K. & Orzechowski, A. Unappreciated role of LDHA and LDHB to control apoptosis and autophagy in tumor cells. Int. J. Mol. Sci. 20, 2085 (2019).
Acknowledgements
We thank E. P. Smith for editing. N.O. is supported in part by KAKENHI (20H03165) and JST-CREST (JPMJCR20H6). This work is supported by NIH grant R01CA255331 and AMED grant Project for Cancer Research and Therapeutic Evolution (P-CREATE; 22ama221112).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Osaka, N., Sasaki, A.T. Beyond Warburg: LDHA activates RAC for tumour growth. Nat Metab 4, 1623–1625 (2022). https://doi.org/10.1038/s42255-022-00709-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s42255-022-00709-3
This article is cited by
-
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Signal Transduction and Targeted Therapy (2023)